CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Placebos +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00317148
NCT00317148Phase 3Completed
CompareCT.gov

Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women

CHU de Quebec-Universite Laval·interventional·Posted Apr 24, 2006·Updated Apr 7, 2017

In Brief

A Phase 3 clinical trial evaluating Placebos and DHEA capsule for Hot Flashes. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHot Flashes
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 24, 2006
Enrollment StartAug 1, 2005
Primary CompletionSep 1, 2006
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.2 years ago

Interventions

Placebosdrug

Placebo capsule

DHEA capsuledrug

One capsule of DHEA